Vimizim EU (Elosulfase alfa Vials) 1mg/ml x 5ml

Vimizim EU (elosulfase alfa) is an enzyme replacement therapy for mucopolysaccharidosis type IVA (Morquio A syndrome). Administered via intravenous infusion, it helps manage symptoms in approved patients. This European-sourced treatment is stored at 2-8°C. Always consult a healthcare provider for suitability.

Strength

1mg/ml x 5ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Biomarin

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Elosulfase alfa is used to treat mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This rare genetic disorder affects the body's ability to break down glycosaminoglycans, leading to skeletal and systemic complications. The therapy helps improve mobility and respiratory function in eligible patients. It is prescribed for long-term management under medical supervision.

Side Effects

Patients receiving elosulfase alfa may experience infusion-related reactions, such as fever, headache, or nausea. These effects are typically managed with premedication and slower infusion rates. Regular monitoring helps minimize discomfort. Individual responses vary, and benefits may take time to become apparent.

Precautions & Warnings

Elosulfase alfa should be handled by healthcare professionals in a controlled setting. Patients with known allergies to the drug or its components should avoid use. Storage at 2-8°C is critical to maintain potency. Always inform your doctor about current medications and medical history before starting treatment.

Avoid Interactions

Limited data exists on drug interactions with elosulfase alfa. However, caution is advised when combining with other intravenous therapies. Alcohol and certain supplements may affect enzyme activity. Always disclose all medications to your healthcare provider to assess potential risks.

Frequently Asked Questions

Elosulfase alfa is used to treat mucopolysaccharidosis type IVA (Morquio A syndrome), a rare genetic disorder affecting bone and tissue development.

It is given as an intravenous infusion by a healthcare professional, typically over several hours.

Common side effects include fever, headache, nausea, and infusion-related reactions.

No, it must be stored between 2-8°C to maintain its effectiveness.

Yes, this medication is only available with a prescription from a licensed healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.